Organization · Venture Capital
PhiFund Ventures
PhiFund Ventures is a New York-based early-stage venture capital firm focused on transforming healthcare through investments in life sciences companies. They specialize in identifying academic intellectual property and supporting companies that advance diagnosis and treatment.
Overview
What PhiFund Ventures does
What PhiFund Ventures is
PhiFund Ventures is a New York-based early-stage venture capital firm focused on transforming healthcare through investments in life sciences companies. They specialize in identifying academic intellectual property and supporting companies that advance diagnosis and treatment.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2021
- Approximate age
- About 5 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find PhiFund Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
PhiFund Ventures as a funder
Investment thesis
PhiFund Ventures focuses on transforming healthcare by turning high-potential academic and early-stage biomedical science into companies that improve diagnosis and treatment. They emphasize collaboration among scientists, physicians, and business professionals to accelerate innovations in life sciences.
Focus narrative
PhiFund Ventures invests primarily in early-stage life sciences companies, focusing on those that can create synergies between scientific research and medical needs. Their investment strategy is centered around companies that are built on strong scientific foundations and address high unmet medical needs, particularly in areas such as CNS therapeutics, dermatology, gene therapy, and diagnostics.
Value beyond capital
PhiFund Ventures adds value to its portfolio companies by leveraging a network of scientists, physicians, and regulatory experts to facilitate the development and commercialization of innovative healthcare solutions. Their approach emphasizes collaboration and strategic guidance to navigate the complexities of the life sciences sector.
Focus and fit
- Stages
- Seed · Series A
- Regions
- North AmericaEurope
Availability
- Currently deploying
- Not published
Portfolio and track record
Portfolio context
Leal Therapeutics: Developing neuro-metabolic therapies for CNS disorders; raised $30 million in Series A (August 2025). Veradermics: Clinical-stage aesthetics and dermatology biopharma; raised $75 million in Series B (December 2024). SciRhom: Autoimmune biotech developing iRhom2-targeting antibodies; raised €63 million in Series A (July 2024). Switch Therapeutics: RNAi medicines company for CNS diseases; participated in Series A (March 2023). Cirsium Biosciences: Focused on plant-based AAV production. Blackrock Neurotech: Developing brain-computer interfaces for movement and communication restoration. Ajna BioSciences: Botanical drug developer for mental health and neurological disorders. Epitor Therapeutics: Epigenetic editing company focused on gene expression regulation.
Common questions
What to know about PhiFund Ventures
Upseed classifies PhiFund Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.